Research & Development
As Multidrug Resistant (MDR-MRSA) bacteria such as Pseudomonas Aeruginosa or Staphylococcus Aureus continue to perplex the medical community, Pharmotech SA offers hope through a collaborative R&D approach with Swiss Primary Scientific Institutions.
With real-world implementation in mind, Pharmotech SA leverages proof- of concept (PoC) clinical trials to bridge the gap between lab work and clinical applications. These small-scale studies identify high-potential drug candidates while revealing key considerations.
Safety - evaluating for potential toxicity, reactions, and side effects
Dosage - determining the optimal dose for the best possible results
Efficacy - assessing the effectiveness against MDR-MRSA bacteria
As Pharmotech SA continues to conduct R&D, perform trials, and develop patents, millions of patients, healthcare professionals, and animals worldwide will benefit. In the interim, the team remains steadfast in all research efforts and go-to-market strategies.